BGI Genomics is a leading genomics research and services company headquartered in Shenzhen, China. It was founded in 1999 as the Beijing Genomics Institute and later renamed BGI Genomics. The company played a significant role in the completion of the Human Genome Project and has since emerged as a global leader in genomics research.

BGI Genomics offers a wide range of products and services related to genomics and life sciences. Its main products include next-generation sequencing platforms, microarray technologies, and DNA synthesis machines. The company also provides various genomic research services, including sequencing, genotyping, gene expression analysis, and bioinformatics analysis.

Operating on a global scale, BGI Genomics has established numerous subsidiaries, joint ventures, and partnerships. One notable subsidiary is Complete Genomics, a US-based company that specializes in human genome sequencing. BGI Genomics has also formed partnerships with academic institutions, research organizations, and healthcare companies worldwide, allowing for collaborative research projects and the exchange of knowledge and expertise.

In terms of market position, BGI Genomics has established itself as a leader in the genomics industry. The company has experienced significant growth in global sales, driven by the increasing demand for genomic research and personalized medicine. It has secured a strong presence in both domestic and international markets, with customers ranging from academic researchers to pharmaceutical companies.

BGI Genomics has achieved several major milestones and accomplishments throughout its history. In 2010, it launched the MGI Tech Co., Ltd., a subsidiary dedicated to developing novel sequencing technologies. The company has also expanded its product lineup, introducing new platforms and technologies to enhance its genomics research capabilities.

As of the latest information available, BGI Genomics continues to be at the forefront of genomics research and services. It is actively involved in various research collaborations and partnerships globally, working towards advancing precision medicine and enhancing our understanding of human health and diseases. The company remains committed to innovation, driving its growth and maintaining its position as a global leader in genomics